Home   >  
Hormone Pathay
  • GPCR/G Protein
∨
  >  
GPR

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

GPR

Chemical Structure Cat. No. Product Name CAS No.
GPR81 agonist 1 Chemical Structure
 BCP36389 GPR81 agonist 1 1620992-67-7
GPR81 agonist 1 is a potent and highly selective GPR81 agonist, with EC50s of 58 nM and 50 nM for human and mouse GPR81, respectively.
TC-G 1001 Chemical Structure
 BCP49127 TC-G 1001 494191-73-0
TC-G 1001 is a potent agonist of GPR35, with EC50s of 26 and 3.2 nM in the β-arrestin and Ca2+ release assay, respectively.
NCRW0005F05 Chemical Structure
 BCP48739 NCRW0005F05 342779-66-2
NCRW0005-F05 is the first GPR139 antagonist (IC50 = 0.21 µM).
ML 145 Chemical Structure
 BCP45167 ML 145 1164500-72-4
ML 145 is a selective antagonist for the GPR35 orphan receptor GPCR (IC50 = 20.1 nM). Over 1000-fold more selective for GPR35 compared to GPR55 antagonists.
SCO-267 Chemical Structure
 BCP41795 SCO-267 1656261-09-4
SCO-267 is a novel GPR40 full agonist, improving liver parameters in a mouse model of nonalcoholic fatty liver disease without affecting glucose or body weight.
AS1269574 Chemical Structure
 BCP43461 AS1269574 330981-72-1
AS-1269574 is a selective, orally available GPR119 agonist with EC50 of 2.5 uM in cell-based cAMP assays.
TAK041 Chemical Structure
 BCP43188 TAK041 1929519-13-0
TAK-041 is a novel Potent and Selective GPR139 Agonist for the Treatment of Negative Symptoms Associated with Schizophrenia.
PSB-SB-487 Chemical Structure
 BCP37990 PSB-SB-487 1399049-81-0
PSB-SB-487 is a potent, allosteric GPR55 antagonist
ML-191 Chemical Structure
 BCP37828 ML-191 931695-79-3
ML-191 is a potent, selective GPR55 antagonist with 160 nM potency for GPR55 and >100-fold selectivity against GPR35, CB1 and CB2.
AMG-009 Chemical Structure
 BCP37558 AMG-009 1027847-67-1
AMG 009 is an orally active, small molecule CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) and DP (D prostanoid) dual antagonist, which was in preclinical development in the US for the treatment of asthma and allergic rhinitis.
123下一页末页共 45 条记录 1 / 5 页 
0086-13720134139